BeyondSpring Inc. reported operational updates for Q1 2026 centering on its flagship drug candidate Plinabulin, which continues clinical development aimed at addressing unmet needs in lung cancer. The company is actively divesting SEED Therapeutics, its Targeted Protein Degradation (TPD) platform, reflecting a strategic refocus. Absent product revenues, the firm sustains activities primarily through licensing and equity financings. The clinical-stage status imposes inherent developmental risks while financial resources remain moderate, with recent cash reserves around $4 million and a current ratio near 1.09. Going forward, regulatory filings and enrollment milestones for confirmatory Plinabulin trials will be key indicators.